Strong Year For Cephalon, But An Uncertain Future Remains
This article was originally published in The Pink Sheet Daily
Executive Summary
The specialty pharma has made plenty of acquisitions and is pursuing late-stage options, but the upcoming loss of its lead product to generic competition may not be filled by the risky pipeline.
You may also be interested in...
Generic Opportunities In 2012 Diluted By Shared Exclusivities
Despite the patent cliff, 2012 is one of the final years of blockbusters going generic, leaving the large generic companies to establish their place in the morphing market.
Cephalon Boosts Cancer Pipeline With Acquisition Valued At Up to $525 Million
The specialty biopharma has gained two promising oncology drugs through the acquisition of privately-held Gemin X
Cephalon’s Nuvigil For Jet Lag Is Pulled Off The Runway; Bipolar Indication Remains On The Horizon
A second “complete response” letter from FDA derails development of the jet lag claim; Cephalon repeatedly has struck out in seeking a new indication to differentiate the wakefulness drug from Provigil.